Context Therapeutics Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| CNTX | BCTX | BOLT | MRKR | CHRS | HBP.TO | |
|---|---|---|---|---|---|---|
| Market cap | 18.70M | 27.86M | 15.42M | 16.84M | 131.36M | 70.27M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -0.5 | -8.2 | -0.3 | -1.9 | -1.3 | -8.4 |
| Price/book | 0.5 | 1.7 | 1.0 | 1.4 | 2.2 | 4.8 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −82.83% | −67.55% | +36.82% | +6.52% | −42.95% | −54.68% |
| Today | +4.90% | +5.98% | −0.46% | +2.76% | +5.54% | 0.00% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All CNTX news ›Context Therapeutics (CNTX) Set to Release Quarterly Earnings on Wednesday
Posted by Sarita Garza on Oct 28th, 2026 Context Therapeutics (NASDAQ:CNTX – Get Free Report) last released its earnings results on Wednesday, August 5th. The company reported ($0.15) earnings per share for the quarter, missing analysts’…
Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202
PHILADELPHIA, May 18, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) ... Context announces buyout of CT-202…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- markets.financialcontent.com1
- themarketsdaily.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 2 articles, not a forecast.